Forbes June 10, 2024
Bruce Japsen

Abbott Laboratories Monday said the U.S. Food and Drug Administration has cleared for sale two new over-the-counter continuous glucose monitoring systems, devices that could bring more access to millions of people with diabetes.

Abbott said its Lingo device is designed for general consumers who are looking to improve their overall health and wellness while the other device cleared by the FDA known as Rio is for adults with Type-2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications. There are more than 38 million Americans with diabetes in the U.S. alone.

“There is no one-size-fits all approach for glucose monitoring, which is why we’ve designed different products for different people – all based on the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Danaher setting up labs to support companion diagnostic development
Q Bio Secures $27M to Expand Full-Body MRI with Mark I Scanner
Advanced diagnostics: Patient-centered innovation
Abbott previews PFA, over-the-counter CGM markets
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner

Share This Article